Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study
机构：[1]Tianjin Med Univ Gen Hosp, Dept Med Oncol, Tianjin, Peoples R China[2]Inner Mongolia Autonomous Reg Peoples Hosp, Dept Med Oncol, Hohhot, Peoples R China[3]First Hosp Shijiazhuang, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China[4]Hebei Univ,Affiliated Hosp,Dept Med Oncol,Baoding,Peoples R China医疗肿瘤内科河北大学附属医院重点学科肿瘤内科[5]Tianjin Med Univ Canc Inst & Hosp, Dept Med Oncol, Tianjin, Peoples R China
第一作者机构：[1]Tianjin Med Univ Gen Hosp, Dept Med Oncol, Tianjin, Peoples R China
推荐引用方式(GB/T 7714)：
Zhong D.,Zhang C.,Zhang Y.,et al.Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study[J].ANNALS OF ONCOLOGY.2020,31:S861-S861.doi:10.1016/j.annonc.2020.08.1656.
APA：
Zhong, D.,Zhang, C.,Zhang, Y.,Shang, Y.,Wang, L.&Huang, D..(2020).Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study.ANNALS OF ONCOLOGY,31,
MLA：
Zhong, D.,et al."Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study".ANNALS OF ONCOLOGY 31.(2020):S861-S861
医学